LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Denmark-based
biotechnology company Genmab A/S (GMXAY.PK, GNMSF.PK) announced that the
European Commission or EC has granted marketing authorization for a new
indication for the use of...
Welcome to the latest edition of our weekly EuroBiotech Report. With the battle for investor support in the AbbVie-Shire takeover tug of war heating up, the Ireland-headquartered biopharma has played up its European roots and rare position in the...
LONDON (dpa-AFX) - GlaxoSmithKline plc (GSK, GSK.L) and Genmab A/S said
Thursday that the U.S. Food and Drug Administration has approved a Supplemental
Biologic License Application for the use of Arzerra, a CD20-directed monoclonal
Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
Arzerra has not yet been approved anywhere for a first-line use, but the companies believe that new data will boost its chances. It is asking for it to be used in combination with an alkylator-based therapy in patients for which a...
The FDA will fast-track review of the drug for use with an alkylator-based therapy for the patients with chronic lymphocytic leukaemia (CLL) who have not received any previous treatment and are inappropriate for fludarabine-based therapy.
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.